verubecestat

Small moleculeexperimental

Verubecestat (MK-8931) was an experimental drug for the treatment of Alzheimer's disease. It is an inhibitor of beta-secretase 1 (BACE1), which, after initial promise proved disappointing. — Wikipedia

Clinical trial activity

5 trials · 1 clinical orgs · 0 marketing orgs

Phase 1

Phase 2

Phase 3

Phase 4

Earliest trial started Dec 1, 2011 (NCT01496170)

Timeline

2010s

Jan 1, 2011
Earliest Phase 1 Sponsor(trial)
Jan 1, 2012
Earliest Phase 2 Sponsor(trial)
Jan 1, 2013
Earliest Phase 3 Sponsor(trial)

Indications

Studied for

Mechanism of action

Beta-secretase 1INHIBITOR
BACE1 inhibitor
- Beta-secretase 1 (BACE1) ↗

Chemistry & pharmacology

Loading structure…

SMILES

CN1C(N)=N[C@](C)(c2cc(NC(=O)c3ccc(F)cn3)ccc2F)CS1(=O)=O

Mol. weight: 409.42 g/mol
Lipinski Ro5: Pass
Rule of 3: No
Chirality: Single Stereoisomer
Inorganic: No
Polymer: No

Oral

Parenteral

Topical

Sources

WikipediaVerubecestat ↗
ChEMBLCHEMBL3301601 ↗

Also known as

mk-8931
mk-8931
mk-8931
n-(3-(3-amino-5,6-dihydro-2,5-dimethyl-1,1-dioxido-2h-1,2,4-thiadiazin-5-yl)-4-fluorophenyl)-5-fluoro-2-pyridinecarboxamide
sch-900931
verubecestat
verubecestat
verubecestat
verubecestat
verubecestat

Clinical trials

NCT ID	Phase	Start date	Sponsor(s)
NCT02910739	Phase 1	Oct 11, 2016	Merck
NCT01953601	Phase 3	Nov 5, 2013	Merck
NCT01739348	Phase 2/Phase 3 (Phase 3)	Nov 30, 2012	Merck
NCT01537757	Phase 1	Mar 1, 2012	Merck
NCT01496170	Phase 1	Dec 1, 2011	Merck

Showing 5 of 5 trials

Page 1 / 1

Organizations

Research & Development (1)

Organization	Org type	Trials	As lead sponsor	Phases	Earliest year
Merck	For profit	5	5	2	2011

1 organizations

Page 1 / 1